drugset / Trial / NCT00087672
A Phase II Study of CC-5013 in Myelofibrosis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
Timeline
- Start
- 2004-07
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |